Allon Therapeutics completes enrolment for Phase II Alzheimer's trial
Allon Therapeutics Inc. announced that enrolment is complete in the Phase II clinical trial evaluating Allon's drug candidate AL-108 as a treatment for Alzheimer's disease. This trial has progressed ahead of schedule and is expected to be the first of Allon's three Phase II efficacy trials to report top line data, with results expected in Q1 2008.
The Company expects that the results from this trial will support further clinical development in pursuit of a treatment for Alzheimer's disease. The 150 subject Phase II trial is a multi-center, double-blind, randomized, placebo-controlled, multiple-dose study to evaluate the safety, tolerability and effect on cognitive function of AL-108 after 12 weeks of intranasal administration in patients with amnestic mild cognitive impairment, the precursor to Alzheimer's.
Allon's Alzheimer's program is unique in that AL-108 targets a fundamental underlying mechanism of neurodegenerative disease and impacts both of the classic hallmarks of Alzheimer's. The Company has established an extensive data-set showing the effects of AL-108 on neurodegeneration and, in particular, both amyloid plaques and neurofibrillary tangles the two pathologies most closely correlated with Alzheimer's disease. In 2006, over $4 billion was spent on approved drugs for Alzheimer's disease; these drugs have only a modest effect on symptoms of the disease.
Other news from the department research and development
